Ilardi F, et al. - The impact of carvedilol (a nonselective β-blocker) vs metoprolol (a selective β1-blocker) on platelet aggregation in patients with acute coronary syndromes (ACS) treated with dual antiplatelet therapy (DAPT) with aspirin and ticagrelor, was assessed. The primary endpoint was epinephrine-induced maximum platelet aggregation (MPA) at 30 days. Between the groups, similar MPA was noted at randomization. The carvedilol group vs metoprolol group showed significantly lower epinephrine-induced platelet aggregation at 30 days, with a trend toward the lower values of ADP-induced MPA. Overall, carvedilol vs metoprolol attenuated residual platelet reactivity in ACS patients.